Related Experiment Video
Updated: Jun 16, 2026

Fetal Echocardiography and Pulsed-wave Doppler Ultrasound in a Rabbit Model of Intrauterine Growth Restriction
Published on: June 29, 2013
Site-specific IGFBP-1 hyper-phosphorylation in fetal growth restriction: clinical and functional relevance
Majida Abu Shehab1, Javad Khosravi, Victor K M Han
1Department of Pediatrics, University of Western Ontario, Ontario, Canada.
Insights
Increased phosphorylation of Insulin-like Growth Factor Binding Protein-1 (IGFBP-1) in fetal growth restriction (FGR) limits Insulin-like Growth Factor-I (IGF-I) bioavailability. This suggests a key mechanism contributing to FGR development.
Area of Science:
- Endocrinology
- Reproductive Biology
- Molecular Biology
Background:
- Insulin-like Growth Factor-I (IGF-I) bioavailability is crucial for fetal growth.
- IGF-I bioavailability is regulated by IGF-binding proteins (IGFBPs), particularly IGFBP-1.
- Phosphorylation of IGFBP-1 can alter its binding affinity to IGF-I.
Purpose of the Study:
- To investigate if site-specific IGFBP-1 phosphorylation patterns differ in fetal growth restriction (FGR).
- To determine the correlation between IGFBP-1 phosphorylation and fetal growth parameters.
- To explore the impact of altered IGFBP-1 phosphorylation on IGF-I binding.
Main Methods:
- Comparison of IGFBP-1 phosphorylation sites and degree in amniotic fluid from FGR and control groups.
- Liquid chromatography-tandem mass spectrometry (LC-MS/MS) for phosphopeptide analysis.
- Surface plasmon resonance (BIAcore) to assess IGFBP-1/IGF-I binding kinetics.
- Structural modeling to predict the impact of phosphorylation on IGF-I interaction.
Main Results:
- Serine phosphorylated IGFBP-1 concentration negatively correlated with birth weight in FGR.
- Significantly higher phosphorylation intensities at Ser101, Ser98/Ser101, and Ser169 in FGR compared to controls.
- Increased IGFBP-1 association and decreased dissociation rates with IGF-I in FGR, indicating tighter binding.
Conclusions:
- Elevated site-specific phosphorylation of IGFBP-1, particularly at Ser98, Ser101, and Ser169, is characteristic of FGR.
- This increased phosphorylation likely enhances IGFBP-1's affinity for IGF-I, reducing IGF-I bioavailability.
- The findings suggest that altered IGFBP-1 phosphorylation is a significant contributor to the pathophysiology of FGR.
Abstract:
Phosphorylation enhances IGFBP-1 binding to IGF-I, thereby limiting the bioavailability of IGF-I that may be important in fetal growth. Our goal in this study was to determine whether changes in site-specific IGFBP-1 phosphorylation were unique to fetal growth restriction. To establish a link, we compared IGFBP-1 phosphorylation (sites and degree) in amniotic fluid from FGR (N = 10) and controls (N = 12). The concentration of serine phosphorylated IGFBP-1 showed a negative correlation with birth weight in FGR (P = 0.049). LC-MS/MS analysis revealed all four previously identified phosphorylation sites (Ser98, Ser101, Ser119, and Ser169) to be common to FGR and control groups. Relative phosphopeptide intensities (LC-MS) between FGR and controls demonstrated 4-fold higher intensity for Ser101 (P = 0.026), 7-fold for Ser98/Ser101 (P = 0.02), and 23-fold for Ser169 (P = 0.002) in the FGR group. Preliminary BIAcore data revealed 4-fold higher association and 1.7-fold lower dissociation constants for IGFBP-1/IGF-I in FGR. A structural model of IGFBP-1 bound to IGF-I indicates that all the phosphorylation sites are on relatively mobile regions of the IGFBP-1 sequence. Residues Ser98, Ser101, and Ser169 are close to structured regions that are involved in IGF-I binding and, therefore, could potentially make direct contact with IGF-I. On the other hand, residue Ser119 is in the middle of the unstructured linker that connects the N- and C-terminal domains of IGFBP-1. The model is consistent with the assumption that residues Ser98, Ser101, and Ser169 could directly interact with IGF-I, and therefore phosphorylation at these sites could change IGF-I interactions. We suggest that site-specific increase in IGFBP-1 phosphorylation limits IGF-I bioavailability, which directly contributes to the development of FGR. This study delineates the potential role of higher phosphorylation of IGFBP-1 in FGR and provides the basis to substantiate these findings with larger sample size.
Related Concept Videos
TGF - β Signaling Pathway
Regulation of Angiogenesis and Blood Supply
PI3K/mTOR/AKT Signaling Pathway
